Copenhagen, 2015-02-26 11:48 CET (GLOBE NEWSWIRE) -- Copenhagen, 26 February 2015 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) today informs that in March 2015 the company will present at the three investor conferences listed below, taking place in London, Paris and Copenhagen, respectively.
At the conferences, representatives from Zealand’s management team will meet with and present to investors, providing an update on the company’s most recent achievements, including the Lyxumia® royalty bond financing of USD 50 million, on the status for the portfolio of both proprietary and partnered medicines in development, as well as on the catalyst outlook for 2015.
Credit Suisse One-on-One Healthcare Conference, London (3-4 March)
Tuesday 3 March: Zealand hosting one-to-one and small group meetings.
Zealand representatives: President and CEO Britt Meelby Jensen and Vice President, Head of IR and Corporate Communications Hanne Leth Hillman
Exane BNP Paribas Healthcare Conference, Paris (17-18 March)
Tuesday 17 March: Zealand group presentation at 16:30 CET and hosting of one-to-one meetings.
Zealand representatives: President and CEO Britt Meelby Jensen and Vice President, Head of IR and Corporate Communications Hanne Leth Hillman
InvestorDagen, Copenhagen (18 March) – Danish Shareholders Association
Wednesday 18 March from 11:30am-7:30pm CET: Zealand group presentation and exhibition at the event.
Please note that no new financial or other material new information relating to Zealand will be disclosed at the above listed conferences.
●●●●●
For further information, please contact:
Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a proprietary pipeline of novel medicines alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory filing for Lyxumia® is planned for Q3 2015 and US/EU filings for LixiLan in Q4 2015.
Zealand proprietary pipeline includes danegaptide (prevention of Ischemic Reperfusion Injury) and the stable glucagon product, ZP4207 (treatment of severe hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
